DR. DOUGLAS EARL LAUX, MD
Osteopathic Medicine at Hawkins Dr, Iowa City, IA

2009026, Oct 22, 2009

Oct 27, 2006

12/091718

Charles W. Caldwell - Columbia MO, US
Huidong Shi - Martinez GA, US
Farahnaz Rahmatpanah - Newport Beach CA, US
Kristen H. Taylor - Columbia MO, US
Douglas E. Laux - Iowa City IA, US
Deiter J. Duff - Columbia MO, US
Juyuan Guo - Columbia MO, US

Curators of the University of Missouri - Columbia MO

C40B 30/04, C12Q 1/68

506 9, 435 6

Differential Methylation Hybridization (DMH) was used to identify novel methylation markers and methylation profiles for hematopoieetic malignancies, leukemia, lymphomas, etc. (e.g., non-Hodgkin's lymphomas (NHL), small B-cell lymphomas (SBCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), etc.). Particular aspects provide novel biomarkers for NHL and subtypes thereof (e.g., MCL, B-CLL/SLL, FL, DLBCL, etc.), AML, ALL and MM, and further provide non-invasive tests (e.g. blood tests) for lymphomas and leukemias. Additional aspects provide markers for diagnosis, prognosis, monitoring responses to therapies, relapse, etc., and further provide targets and methods for therapeutic demethylating treatments. Further aspects provide cancer staging markers, and expression assays and approaches comprising idealized methylation and/or patterns” (IMP and/or IEP) and fusion of gene rankings.